Efficacy and safety of alfaxalone compared to propofol in canine refractory status epilepticus: a pilot study

被引:0
|
作者
Al Kafaji, Tania [1 ]
Corda, Andrea [2 ]
Charalambous, Marios [3 ,4 ]
Murgia, Elsa [1 ]
Tartari, Ilaria [1 ]
Puci, Mariangela [5 ]
Debidda, Pasquale [1 ]
Gallucci, Antonella [1 ]
机构
[1] Vet Neurol Ctr La Fenice, Selargius, Italy
[2] Univ Sassari, Vet Teaching Hosp, Dept Vet Med, Sassari, Italy
[3] Blaise Vet Referral Hosp, Small Anim Clin, Birmingham, England
[4] Leibniz Univ Hannover, Dept Vet Med, Hannover, Germany
[5] Univ Sassari, Dept Med Surg & Pharm, Clin Epidemiol & Med Stat Unit, Sassari, Italy
关键词
status epilepticus; alfaxalone; propofol; dogs; seizures; NEUROACTIVE STEROIDS; TONIC INHIBITION; DOGS; MANAGEMENT; SEIZURES; INFUSION; RECEPTORS; CATS;
D O I
10.3389/fvets.2024.1383439
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Introduction Refractory status epilepticus (RSE) is defined as seizure activity that is minimally responsive to first- or second-line antiseizure medications. Constant rate infusion (CRI) intravenous propofol (PPF) is commonly used to treat RSE in dogs and cats. The antiseizure activity of alfaxalone (ALF) in RSE has been demonstrated in various experimental studies. This study compared the clinical efficacy and safety of intramuscular administration followed by CRI infusion of ALF with intravenous administration followed by CRI infusion of PPF to treat canine RSE.Materials and methods This was a multicenter, prospective, randomized clinical trial of client-owned dogs referred for status epilepticus that did not respond to first- and second-line drugs. Animals with suspected or confirmed idiopathic or structural epilepsy were included. The dogs were randomly assigned to either the PPF or ALF treatment groups and each group received drug CRI infusions for 6 h. Drug dosages were progressively reduced by 25% every hour from the third hour until suspension after 6 h. Patients were classified as responders or non-responders based on the relapse of epileptic seizures during the 24 h therapy infusion or within 24 h of drug suspension. Univariate statistical analyses were performed.Results Twenty dogs were enrolled in the study. Ten (10/20) dogs were randomly allocated to the PPF group and 10 (10/20) to the ALF group. Successful outcomes were obtained in six (6/10) patients in the PPF group and five (5/10) patients in the ALF group. Adverse effects were recorded in six (6/10) and three (3/10) animals in the PPF and ALF groups, respectively. No statistically significant differences in outcomes or the presence of adverse effects were observed between the groups.Discussion The results of this preliminary study suggest that ALF can be considered a valid and safe alternative to PPF for the treatment of RSE in dogs, with the additional advantage of intramuscular administration. However, caution should be exercised when using these drugs to provide airway and hemodynamic support.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Safety and Efficacy of Intravenous Lacosamide for Adjunctive Treatment of Refractory Status Epilepticus: A Comparative Cohort Study
    Sutter, Raoul
    Marsch, Stephan
    Rueegg, Stephan
    CNS DRUGS, 2013, 27 (04) : 321 - 329
  • [32] Efficacy and safety of perampanel in refractory and super-refractory status epilepticus: cohort study of 81 patients and literature review
    Siew-Na Lim
    Tony Wu
    Wei-En Johnny Tseng
    Hsing-I Chiang
    Mei-Yun Cheng
    Wey-Ran Lin
    Chia-Ni Lin
    Journal of Neurology, 2021, 268 : 3744 - 3757
  • [33] Midazolam and thiopental for the treatment of refractory status epilepticus: a retrospective comparison of efficacy and safety
    Flavio Bellante
    Benjamin Legros
    Chantal Depondt
    Jacques Créteur
    Fabio Silvio Taccone
    Nicolas Gaspard
    Journal of Neurology, 2016, 263 : 799 - 806
  • [34] Efficacy and safety of perampanel in refractory and super-refractory status epilepticus: cohort study of 81 patients and literature review
    Lim, Siew-Na
    Wu, Tony
    Tseng, Wei-En Johnny
    Chiang, Hsing-, I
    Cheng, Mei-Yun
    Lin, Wey-Ran
    Lin, Chia-Ni
    JOURNAL OF NEUROLOGY, 2021, 268 (10) : 3744 - 3757
  • [35] Propofol treatment in adult refractory status epilepticus. Mortality risk and outcome
    Power, Kjersti Nesheim
    Flaatten, Hans
    Gilhus, Nils Erik
    Engelsen, Bernt A.
    EPILEPSY RESEARCH, 2011, 94 (1-2) : 53 - 60
  • [36] Propofol-induced refractory status epilepticus at remission age in benign epilepsy with centrotemporal spikes A case report and literature review
    Lu, Lu
    Xiong, Weixi
    Zhang, Yingying
    Xiao, Yingfeng
    Zhou, Dong
    MEDICINE, 2019, 98 (27)
  • [37] The efficacy of topiramate in adult refractory status epilepticus: Experience of a Tertiary Care Center
    Synowiec, Andrea S.
    Yandora, Kristin A.
    Yenugadhati, Vamsi
    Valeriano, James P.
    Schramke, Carol J.
    Kelly, Kevin M.
    EPILEPSY RESEARCH, 2012, 98 (2-3) : 232 - 237
  • [38] Effectiveness and safety of Perampanel in refractory status epilepticus: a case series
    Renna, Rosaria
    Andreone, Vincenzo
    Barone, Paolo
    Penza, Pietro
    NEUROLOGICAL SCIENCES, 2025, 46 (02) : 879 - 885
  • [39] Efficacy of topiramate in children with refractory status epilepticus
    Kahriman, M
    Minecan, D
    Kutluay, E
    Selwa, L
    Beydoun, A
    EPILEPSIA, 2003, 44 (10) : 1353 - 1356
  • [40] Green urine appearance in a patient with refractory status epilepticus due to propofol infusion Green urine due to propofol
    Demir, Turgay
    Aslan, Kezban
    Balal, Mehmet
    Bicakci, Sebnem
    Bozdemir, Hacer
    JOURNAL OF CLINICAL AND ANALYTICAL MEDICINE, 2018, 9 (02) : 150 - 152